Annovis Bio stock reacts to webinar plan and steep discount to analyst targets

Annovis Bio stock (ISIN US0360431013) is trading around 1.38 USD as of September 4, 2026 on the New York Stock Exchange, far below the roughly 12.00 USD consensus price target compiled by MarketBeat that implies about 768 percent upside from current levels according to the portal’s latest overview.

Corporate update webinar and recent figures

According to data compiled by MarketBeat on September 4, 2026, Annovis Bio plans to host a corporate update webinar on September 2, 2026, giving investors a chance to hear management’s latest view on its neurodegeneration drug pipeline and financial position.

The same MarketBeat summary reports that Annovis Bio recently provided second quarter 2026 corporate updates, indicating that the figures discussed in that communication represent the most current reported results for the company within the present freshness window, although detailed revenue and earnings numbers are not broken out in the snippet and therefore are not used here as core current key figures.

Analyst view and valuation gap

MarketBeat’s analyst consensus shows an average rating score of 2.25 for Annovis Bio, based on two buy ratings, one hold rating and one sell rating as of the latest update, underscoring a mixed but overall cautiously positive stance among covering analysts.

In the same overview, the consensus price target for Annovis Bio stands at about 12.00 USD per share compared with the current price level around 1.38 USD, implying roughly 768.0 percent upside potential; this quantified gap highlights how deeply the stock trades below the expectations of the analyst group that follows the company.

For retail investors, the magnitude of that discount makes the upcoming corporate update particularly relevant, because any new data points on the company’s pipeline or cash runway could either reinforce or challenge the assumptions embedded in those targets.

Share performance and market backdrop

MarketBeat notes that since a prior reference point, Annovis Bio shares have decreased by 59.7 percent and are now trading at about 1.3825 USD, illustrating how the stock has significantly underperformed over that period and leaving it near the lower end of its historical trading range.

Such a drop in market value, combined with a clinical stage profile and a focus on complex indications like Alzheimer’s disease and Parkinson’s disease, typically reflects both trial outcome risks and changing investor appetite for small-cap biotechnology names rather than any single event, which is why updated guidance and trial timelines in the second quarter 2026 communication are central to the story.

Pipeline focus: Buntanetap and other candidates

According to the Annovis Bio company profile on Yahoo Finance, the company is a clinical stage drug platform developer focused on neurodegenerative diseases, with its lead product candidate Buntanetap in phase 3 trials for Alzheimer’s disease and in open-label phase 3 studies for Parkinson’s disease as of the latest profile update.

The same profile lists additional candidates, including ANVS405, which is in phase 2 and phase 3 clinical trials for traumatic brain injury and stroke indications, and ANVS301, which has completed a phase 1 clinical trial aimed at increasing cognitive capability in later stages of Alzheimer’s disease and dementia; together these assets underline that Annovis Bio’s valuation is closely tied to clinical trial outcomes rather than current product revenue.

Stock level and investor perspective

With Annovis Bio stock trading near 1.38 USD on the New York Stock Exchange as of September 4, 2026 compared to an analyst consensus target around 12.00 USD, the shares reflect both the substantial risks of late-stage neurodegeneration drug development and the potential reward that analysts see if key trials such as the Buntanetap phase 3 programs deliver convincing data and support future regulatory filings.